menu
    • menu

    Company profile for Agenus

    NEW Drugs in Dev: 21
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Agenus is an immuno-oncology company designed to deliver innovation with speed for patients with cancer. We have a unique portfolio of antibodies, vaccines, cell therapies (through our AgenTus Therapeutics subsidiary) and adjuvants designed to treat cancers with optimal combinations. In addition to our broad portfolio, we have an accomplished team of scientists, novel technology platforms and end-to-end capabilities from new t...
    Agenus is an immuno-oncology company designed to deliver innovation with speed for patients with cancer. We have a unique portfolio of antibodies, vaccines, cell therapies (through our AgenTus Therapeutics subsidiary) and adjuvants designed to treat cancers with optimal combinations. In addition to our broad portfolio, we have an accomplished team of scientists, novel technology platforms and end-to-end capabilities from new target discovery to GMP manufacturing.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AgenusUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    3 Forbes Road Lexington, MA 02421-7305
    Telephone
    Telephone
    781.674.4400
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://agenusbio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/agenus
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/hashtag/agenus?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Agenus To Host Mar 2026 Webcast On BOT + BAL Strategy
    Agenus To Host Mar 2026 Webcast On BOT + BAL Strategy

    26 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260326480611/en/Agenus-to-Host-March-2026-Stakeholder-Webcast-Harnessing-the-Immune-System-to-Advance-BOT-BAL-Across-Tumor-Types-and-Expand-Patient-Access

    BUSINESSWIRE
    26 Mar 2026
    Share Share
    Agenus Unveils Botensilimab-Balstilimab at AACR
    Agenus Unveils Botensilimab-Balstilimab at AACR

    17 Mar 2026

    // BUSSINESSWIRE

    https://www.businesswire.com/news/home/20260317452517/en/Agenus-Announces-Upcoming-AACR-2026-Presentation-Evaluating-Botensilimab-Plus-Balstilimab-in-First-Line-MSS-Metastatic-Colorectal-Cancer

    BUSSINESSWIRE
    17 Mar 2026
    Share Share
    Agenus Reports 2025 Results; BOT+BAL Advances To Phase 3
    Agenus Reports 2025 Results; BOT+BAL Advances To Phase 3

    16 Mar 2026

    // BUSSINESSWIRE

    https://www.businesswire.com/news/home/20260316750682/en/Agenus-Reports-2025-Results-BOTBAL-Advances-to-Phase-3-and-Early-Access-Programs-Expand-Globally-with-Initial-Revenues-Recognized

    BUSSINESSWIRE
    16 Mar 2026
    Share Share
    Agenus to Provide Q4 and Year-end 2025 Financial Report
    Agenus to Provide Q4 and Year-end 2025 Financial Report

    04 Mar 2026

    // BUSSINESSWIRE

    https://www.businesswire.com/news/home/20260304473547/en/Agenus-to-Provide-Fourth-Quarter-and-Year-end-2025-Financial-Report-and-Corporate-Update

    BUSSINESSWIRE
    04 Mar 2026
    Share Share
    Agenus Shows Survival Stratification in MSS mCRC
    Agenus Shows Survival Stratification in MSS mCRC

    19 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260219390538/en/Agenus-Presents-Biomarker-Data-Demonstrating-Survival-Stratification-in-MSS-mCRC-and-Other-Immunologically-Cold-Tumors-Treated-with-BOTBAL

    BUSINESSWIRE
    19 Feb 2026
    Share Share
    Agenus To Unveil Systemic, Tumor Inflammation Biomarker Data
    Agenus To Unveil Systemic, Tumor Inflammation Biomarker Data

    09 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260209269639/en/Agenus-to-Present-New-Data-at-AACR-IO-Exploring-Systemic-and-Tumor-Inflammation-Biomarkers-with-BOTBAL-in-Immunologically-Cold-Tumors

    BUSINESSWIRE
    09 Feb 2026
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search